Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferasirox (DFX)
All‐cause mortality (n/N)
Summary of findings: Comparison 3 ‐ deferiprone (DFP) showed no clear difference in all‐cause mortality (n/N) compared with deferasirox (DFX) (low certainty).
1 finding from 1 review
- Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes onlyRD 01 study · 390 participantsLow